Drug Profile


Alternative Names: BMS-354825; Sprycel

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; Dana-Farber Cancer Institute; Massachusetts General Hospital; Otsuka Pharmaceutical; Sarcoma Alliance for Research through Collaboration; University of Texas M. D. Anderson Cancer Center; Weill Cornell Medical College
  • Class Amides; Antineoplastics; Chlorobenzenes; Piperazines; Pyrimidines; Small molecules; Thiazoles
  • Mechanism of Action Bcr-abl tyrosine kinase inhibitors; EphA2 receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Proto oncogene protein c-kit inhibitors; Src-Family kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic myeloid leukaemia; Acute lymphoblastic leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute lymphoblastic leukaemia; Chronic myeloid leukaemia
  • Phase III Prostate cancer
  • Phase II Breast cancer; Cholangiocarcinoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Myeloproliferative disorders; Sarcoma
  • Phase I/II Glioblastoma; Non-Hodgkin's lymphoma
  • Phase I Colorectal cancer; Leukaemia; Mesothelioma; Multiple myeloma; Non-small cell lung cancer
  • No development reported Malignant melanoma
  • Discontinued Pancreatic cancer; Scleroderma

Most Recent Events

  • 03 Mar 2017 Bristol-Myers Squibb and M.D. Anderson Cancer Center completes a phase II trial in Myeloproliferative disorders (Second-line therapy or greater, Newly diagnosed) in USA (PO) (NCT00255346)
  • 03 Mar 2017 M.D. Anderson Cancer Center and Bristol-Myers Squibb complete a phase I trial in Colorectal cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (NCT00501410)
  • 01 Feb 2017 The European Patent Office upheld decision for European patent no. 1 169 038 for dasitinib as the patent was found to be invalid
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top